García-Rodríguez M A, Cubillo-Durán E, Moreno-Camelo S, Mata-Román L, Muñoz-Moreno M F, Cáceres-Pereira A
Medicina de Familia y Comunitaria, Equipo de Atención Primaria Medina del Campo Urbano, Valladolid, España.
Semergen. 2013 Jul-Aug;39(5):252-8. doi: 10.1016/j.semerg.2012.09.006. Epub 2013 Jan 16.
To describe the results of implementing a pilot screening program, in the Castilla y León, for colorectal cancer (CRC) with the faecal occult blood test (iFOBT) using a quantitative immunological latex agglutination assay.
The study population included 4930 persons between 50-69 years from the Basic Health Area of Medina del Campo. Colonoscopy was performed on those who had a positive iFOBT. The rates of participation were calculated, positivity, acceptance of colonoscopy, detection of lesions, percentages and predictive positive value (PPV) of the test.
A total of 2241 (46.33%) people took part. There were 138 (6.15%) positive iFOBT. The rate acceptance of the colonoscopy was 99.27%. CRC was detected in 12 patients (91.66% in early stages), a high risk adenoma (HRA) in 42, and a low risk adenoma (LRA) in 34. The rates of detection were for CRCwas 5.35‰, 18.74‰ for HRA, 15.17‰ for LRA, and 39.26‰ for all kinds of adenoma. The PPV was 8.69% for CCR, 30.43% for HRA and 24.63% for LRA.
The CRC screening program is feasible in our context. The iFOBT indicators are superior to those of other studies performed using the classic test. The high rates of detection of CRC, and all kinds of adenoma would be enough to justify the study. These together with the diagnosis of CRC in the early stages could lead to a reduction of the mortality.
描述在卡斯蒂利亚-莱昂开展的一项试点筛查项目的结果,该项目采用定量免疫乳胶凝集试验,通过粪便潜血试验(iFOBT)筛查结直肠癌(CRC)。
研究人群包括来自梅迪纳德尔坎波基本卫生区的4930名50至69岁的人员。对iFOBT呈阳性的人员进行结肠镜检查。计算参与率、阳性率、结肠镜检查的接受率、病变检出率、各类腺瘤的百分比及预测阳性值(PPV)。
共有2241人(46.33%)参与。iFOBT阳性者有138人(6.15%)。结肠镜检查的接受率为99.27%。检测出12例CRC患者(91.66%为早期),42例高危腺瘤(HRA),34例低危腺瘤(LRA)。CRC的检出率为5.35‰,HRA为18.74‰,LRA为15.17‰,各类腺瘤的总检出率为39.26‰。CCR的PPV为8.69%,HRA为30.43%,LRA为24.63%。
CRC筛查项目在我们的环境中是可行的。iFOBT指标优于使用经典试验进行的其他研究。CRC及各类腺瘤的高检出率足以证明该研究的合理性。这些结果连同早期CRC的诊断可能会降低死亡率。